Navigation Links
Developing a Safer and More Effective Way to Deliver Rabies Antibodies
Date:2/5/2009

INCHEON, South Korea, Feb. 5 /PRNewswire/ -- The Centers for Disease Control and Prevention (CDC) and Celltrion, Inc., a South Korean biopharmaceutical company, have signed a Letter of Intent to permit joint research on the development of novel antibodies to protect people exposed to the rabies virus.

Medical attention for a person exposed to rabies is a two-step procedure. First, rabies immune globulin (RIG) is given to provide immediate antibodies neutralizing the rabies virus. Thereafter, the patient receives five doses of vaccine to build active immunity against the rabies virus.

Active immunity is detectable after the first week of vaccination so RIG is essential at the first stage of medical attention before a person develops their own antibodies from vaccine.

There are currently two types of RIG: human and equine. Human RIG can sometimes be in short supply due to manufacturing restrictions. It is expensive, and there are regulatory concerns because it comes from human blood. Because equine RIG is derived from horses, there are concerns that it may not provide the proper antibody response, and there are international animal care and use issues because of the involvement of horses in its production. In developing countries, where the majority of human rabies cases occur, both types of RIG are frequently unavailable.

The CDC/Celltrion collaboration addresses these problems by using cell culture to manufacture RIG of a new generation, which is expected to be safer, more effective and affordable.

"The CDC is excited to begin a novel research collaboration with Celltrion on the development of additional products that can provide immunity to rabies. We believe this effort holds great public health promise toward the prevention of this deadly disease, especially in developing countries," said Charles E. Rupprecht, V.M.D., chief of the CDC's Rabies Program.

Rabies is a viral disease of mammals which is transmitted through the bite of infected animals. The virus infects the central nervous system, causing inflammation of the brain and ultimately death, if medical assistance is not sought promptly after the exposure to prevent the disease. Rabies is particularly prevalent in Eastern Europe, Asia, South America, and Africa. An estimated 40,000 to 70,000 people die of the disease each year, mainly in Asia and Africa.

About Celltrion: Celltrion, established in 2002, is a contract manufacturing organization with its headquarters in Incheon, South Korea. Celltrion, an emerging leader in the biopharmaceutical industry, is dedicated to providing high quality services to accelerate product development, while offering scalable manufacturing capabilities for our clients and business partners. Celltrion is also investing in research and development of its own products in order to develop into a fully integrated biotechnology company. For more information, please visit Celltrion's website at http://www.celltrion.com.

     For additional information, please contact:
     Seung-Suh (Stanley) Hong, Ph.D.
     Senior Vice President, Business Development
     Celltrion, Inc. (USA)
     E-mail:  seungsuh.hong@celltrion.com
     Tel:  +1-650-766-2307

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of Celltrion as of the date of this release. These forward- looking statements are no guarantees for future performance, and the forward- looking events discussed in this press release may not occur. Celltrion disclaims any intent or obligation to update any of these forward-looking statements.


'/>"/>
SOURCE Celltrion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
2. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
3. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
4. Free CME-certified Webcast: Making Your Case: Up-to-date Answers for Developing Trends in PCI
5. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
6. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
7. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
8. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
9. Iowa State researchers developing system to efficiently convert biomass to ethanol
10. Pharmaceuticals & Biotechs to Share Insights for Developing Leaders in a Fast-Paced, Competitive Industry
11. Developing Sales Leaders: Benchmarks Reveal Tactics that Will Propel Your Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs ... to include an array of biochemical analyses critical for Lead Discovery. The ... hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, and ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
(Date:2/23/2017)... Capitol Hill neighborhood, with its swanky shops, parks and cafés, might ... salon to set up shop. But there,s Hair Fairies ... on E Madison Ave, and CEO Maria Botham ... we pride ourselves on being a destination for parents and ... associated with lice. Everyone can get lice – it doesn,t ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, Inc. has received ... SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. The adjunctive seizure ... periods of rest. A lightweight, non-invasive monitor is placed on the belly of ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 Report Highlights The global ... $8.3 billion in 2016 at a compound annual growth ... Report Includes - An overview of the global market ... data from 2015 and 2016, and projections of compound ... the market on the basis of product type, source, ...
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
Breaking Biology News(10 mins):